Advertisement

Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher’s disease

  • Mercedes Roca-Espiau
  • Marcio Andrade-Campos
  • Jorge J. Cebolla
  • Laura López de Frutos
  • Blanca Medrano-Engay
  • Maria-Pilar López-Royo
  • Pilar GiraldoEmail author
Open Access
Research article
  • 276 Downloads

Abstract

Background

Chronic fatigue (CFg) is a prevalent symptom in Gaucher disease (GD) at diagnosis (79%) and remains in a quarter of patients after years of therapy. Bone abnormalities are present in over 70% and peripheral neuropathy in about 11% of the patients, which contributes to the disabling and debilitating complications. Our hypothesis is that other factors such as muscle-tendinous weakness could have influence in the development of CFg.

Methods

We have evaluated the fiber structure and elasticity of muscle-tendinous unit by strain-elastography (S-ELA) and analyzed their influence in the CFg. S-ELA study was performed in Achilles tendon in 25 type 1 and two type 3 GD patients, all of them with fatigue and were on enzymatic replacement therapy for mean 13 years; simultaneously, bone marrow burden by MRI and calcaneus ultrasound densitometry were evaluated. Blood cell counts, plasma biomarkers, GBA1 genotyping, and SF36 quality of life scale (QoL) were also performed. Statistical analysis: descriptive and comparative test.

Results

All patients showed a normal Achilles tendinous structure. Abnormal stiff grade 2–3 was found in 17/27 (62.9%); in 11/27 (40.7%) of patients, the alteration was bilateral. There were no correlations between the S-ELA results to other variables; nevertheless, a significant correlation between the degree of tendon hardness and the low score on the QoL scales (p = 0.0035) was found. The S-ELA is a sensitive painless, fast, and low cost method to detect muscle-tendinous subclinical dysfunction that could contribute to CFg in GD. The identification of subclinical tendon alteration would be a sign of alarm, focused on the risk of development of bone complications.

Conclusion

Intratendinous alteration in strain-elastography is an independent variable in GD patients with persistent fatigue.

Keywords

Gaucher disease Fatigue Strain-elastography Achilles tendon stiffness QoL 

Abbreviations

BMD

Bone mineral density

BUA

Broad ultrasound attenuation

CCL18/PARC

`Chemokine (C-C motif) ligand 18/pulmonary and activation-regulated chemokine

CEICA

Ethical Committee of Aragon Research Community

CFg

Chronic fatigue

ChT

Chitotriosidase activity

ERT

Enzymatic replacement therapy

GD

Gaucher disease

GD1

Type 1 Gaucher disease

GD2

Type 2 Gaucher disease

GD3

Type 3 Gaucher disease

Lyso Gb1

Plasma glucosylsphingosine

MRI

Magnetic resonance imaging

QoL

Quality of life

S-ELA

Strain-elastography

SF-36

Short Form questionnaire

S-MRI

Spanish MRI score

SPSS

Statistical Package for the Social Sciences

UPLC

Liquid chromatography gradient

Background

Chronic fatigue (CFg) is the most frequent symptom of patients suffering from Gaucher disease (GD) (79% [1]); the use of enzymatic replacement therapy (ERT) has changed the natural history of the disease; its long-term use leads to an improvement of visceral, hematological, and bone symptomatology; and the majority of type1 (GD1) patients achieves the goals of therapy. However, in several patients on long-term ERT, the CFg is still present in almost one-quarter of them (24.5%) [1, 2].

There is limited information about the cause of CFg, although it is mainly attributed to hypermetabolism, myopathy, or an increase in different plasma cytokines concentrations [2, 3]. Nevertheless, there are several factors such as anemia, pain, depression, anxiety, sleep disturbances, emotional distress, physical activity, or medication side effects that could be involved [2, 3]). Bone disease is present in over 70% of the GD patients; in addition, peripheral neuropathy has been described in about 11% of them, which contributes to the disabling and debilitating complications in GD1 [4, 5]. However, other factors including muscle-tendinous weakness could have influence in the development of fatigue. The prevention of bone-related adverse events such as osteoporosis, pathological fractures, deformation, and osteonecrosis remains as a clinically meaningful need that has not been solved yet and which has an important impact on the quality of life (QoL) [6, 7]. The use of long-term ERT decrease the incidence of intraosseous vascular complications; however, to date, there are no good prognostic markers to identified patients at high risk and even patients on ERT can develop bone complications.

Our hypothesis is that other factors including muscle-tendinous weakness could have influence on the development of fatigue. Only a few studies have evaluated the fatigue in GD, and objective quantification has been performed in the previously mentioned studies ([3].

The aim of this study is to evaluate the myotendinous unit in a group of adult GD patients with CFg, by a simple, non-invasive new technology based on strain-elastography (S-ELA) technique which allows the assessment of the biomechanical and structural properties of tissues by measuring their stiffness. A secondary objective is to study the correlation of the results of the S-ELA study with the main characteristic parameters related to bone disease.

Patients and methods

Design and studied population

This study was designed as a cross-sectional case-control, in 25 adults suffering from GD1 and 2 GD type 3 patients, diagnosed and follow-up periodically in our Expert Unit on Lysosomal diseases. All patients were diagnosed by enzymatic and genotyping studies; also, they were evaluated and followed according to the Spanish Guidelines [8] which include clinical, biological, hematological, and biomarkers evaluation every 6 months and bone marrow burden study by magnetic resonance imaging (MRI), control of visceral size by abdominal MRI, and ultrasound bone densitometry every year.

A total of 12 females and 15 males were included (mean age = 41.0 years old, 18.0–62.0 years old). Six patients were splenectomized before the ERT. All of them reported symptomatic CFg despite of several years under treatment (mean 13.0 years, 2.0–25.0 years).

The control group was composed by 20 subjects, with a gender ratio 1/1 and a mean age of 45.0 years old; 18.0–59.0 years old).

In all patients, a clinical interview and physical examination have been performed, taking special attention to the presence of neurological manifestations, therapy of GD, previous history of diabetes, associated endocrine disorders, other comorbidities, or concomitant treatments with steroids. A control group of 20 healthy subjects matched by gender and age were also studied.

All individuals and controls provided written informed consent and the Aragon regional government’s Ethics Committee for Clinical Research, (Zaragoza, Spain) approved the study. The research was conducted in accordance with the principles stated in the Declaration of Helsinki–Ethical Principles for Medical Research Involving Human Subjects, Helsinki, Finland, 1964 and as amended in Fortaleza, Brazil, 2013.

Strain-elastography exam

All patients underwent an exam of both Achilles tendons with real-time tissue S-ELA procedure (Hitachi system EUB-8500, with L54 M transducer, frequency 6–13 MHz) and gray-scale sonographic findings performed simultaneously (B mode) [9, 10].

Longitudinal and axial scans in three areas of Achilles tendon (in the proximal area near the myotendinous junction, in the middle, and in the distal area of the insertion of the tendon in the calcaneus bone) enabled the assemblage of several integrated images to evaluate its morphological structure, as well as its stiffness and to classify it using a semi-quantitative score of different colors to represent stiff tissue (blue, grade 1) to more soft tissue (green-yellow, grade 2) and (yellow-red, grade 3) [9] (see Fig. 1).
Fig. 1

Strain-Elastography. a Normal stiffness. b Abnormal elasticity greater deformability. Red color. c Morphological and stiffness alteration

Bone assessment

The bone marrow was evaluated by MRI following the Spanish MRI score (S-MRI) protocol [11] and bone mineral density (BMD) by the mechanical energy transmitted by the bone expressed in broad ultrasound attenuation (BUA) [12]. According to reference tables, the values then have converted to a T-score or a Z-score.

Visceral volume

Abdominal MRI to determine liver and spleen volume have been performed at the same time.

Blood examination

Blood cell counts, basic biochemical determinations including iron and ferritin levels, liver enzymes, lipid profile, and plasma biomarkers related to GD were performed.

Among GD plasma biomarkers, it were analyzed the chitotriosidase activity (ChT) using 4-methylumbelliferyl-β-d-N,N′,N″-triacetylchitotrioside at non-saturating concentrations to avoid substrate inhibition [13]. The concentrations of chemokine (C-C motif) ligand 18/pulmonary and activation-regulated chemokine (CCL18/PARC) through ELISA technique [14] and glucosylsphingosine (Lyso-Gb1) were determined by a non-laborious method using chromatography-grade methanol and d-glucosyl-β-1,1′-d-erythro-sphingosine-d5 as internal standard, then separated by liquid chromatography system and detected and quantified by coupled mass spectrometry equipment [15].

Quality of life evaluation

The application of the Spanish version of the Health Survey SF-36 questionnaire [16] was performed at the time of the S-ELA. The questionnaire contains 36 items divided in eight health domains: physical function, role limitation due to physical problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. The eight domains can be used to provide physical and mental component summary scores. Each category was scored on a scale of 0–100 were 0 represent the worst overall health status and 100 the best health status. To determine the variability in the questionnaire scores, we have compared the results obtained in the patients with the values published for the Spanish general population [16].

Statistical analyses

Statistical analyses were performed using SPSS (SPSS version 21.0, IBM®, USA) software. Qualitative variables were given as frequencies and percentages and compared using Chi-squared test. Quantitative variables were analyzed for normal distributions by the Kolmogorov-Smirnov test. Normally distributed variables were given as mean and standard deviation and correlated using Pearson test.

All statistical tests considered and took as bilateral significance a level of α = 0.05.

Results

Demographical characteristics

The general characteristics are detailed in Additional file 1: Table S1. All the patients achieved for the long-term hematological and visceral goals of therapy; none of them registered anemia or iron lack, and no bone crisis has been registered in the 2 years previous. Concomitant chronic diseases were described in 13 patients (48.1%).

Strain-elastography assessment

The tendons in the 20 healthy subjects show a blue color (grade 1), consistent with normal stiff tendon tissue. Both Achilles tendons were examined (54) in all the 27 patients; alterations in stiffness were observed in 17 (62.9%) patients, (registered as intratendinous color alterations). The gradation according to S-ELA method was grade 3: 12/54, grade 2: 16/54, and grade 1: 26/54. Globally, 28 tendons showed alterations in the S-ELA study, 11 (40.7%) patients showed both tendons affected, six (22.2%) only one, and ten (37.1%) showed no alterations at all. The ultrasound gray scale showed no changes in the fibrillar pattern, tendon thickness, or echo-structure. The detailed data are shown in Table 1.
Table 1

General data

Patient

S-MRI

R-S-ELA grade

L-S-ELA grade

T-score

Z-score

ChT nmol/mL/h NR: 4.0–133.0

CCL18/PARC ng/mL NR: 12.0–165.0

Lyso Gb1 ng/mL NR: < 0.88

Hb g/dL

Ferritin ng/mL NR: 15–250

011

12

1

1

− 0.60

0.09

126

62

1.56

12.8

201

02

2

1

1

1.51

1.37

63

55

2.50

13.8

353

03

5

2

2

− 0.42

− 0.42

50

73

< 0.88

17.3

300

04

9

3

3

− 0.59

− 0.27

6575

553

39.57

15.5

114

05

11

3

2

− 1.95

− 1.66

1697

360

40.95

13.8

2000

06

2

1

1

− 0.80

0.39

96

76

1.50

14.0

93

07

0

2

2

1.07

1.45

377

99

3.10

13.8

553

08

0

2

1

− 0.61

− 0.71

394

86

6.50

13.8

353

09

15

3

1

− 2.43

− 1.47

208

150

50.32

14.1

29

10

6

1

2

−  2.50

− 1.8

5136

529

131.25

12.6

385

11

6

3

3

− 2.50

− 1.7

351

233

4.20

12.8

60

12

8

2

2

0.42

0.61

1368

239

15.10

15.5

360

13

4

1

1

− 2.64

− 1.59

1840

328

21.90

13.5

220

14

18

3

3

− 2.06

− 2.32

265

2.73

13.8

250

15

8

3

2

− 1.40

− 1.43

974

265

2.80

13.5

74

16

8

3

1

1.12

1.15

1849

474

57.90

13.3

700

17

4

1

1

− 1.49

− 0.59

337

76

5.10

12.2

65

18

11

2

1

− 0.60

− 1.54

2972

925

144.0

14.1

200

19

0

1

1

− 0.98

0.31

46

31

< 0.88

13.8

50

20

0

1

1

0.24

− 0.15

809

88

9.90

15.7

74

21

7

3

2

1.27

0.85

5740

526

124.6

13.0

 

22

12

1

1

− 2.29

− 1.96

1700

293

60.10

14.0

30

23

8

1

1

0.56

0.56

90

60

3.5

13.3

91

24

12

1

1

− 1.56

− 2.24

491

201

13.4

14.7

27

25

7

2

2

0.74

3.13

541

232

4.5

13.6

1733

26

13

2

1

0.76

2.2

1554

776

124.5

14.4

1349

27

4

1

1

− 0.21

− 0.68

108

53

< 0.88

13.5

350

Total

7.1

0–18

  

− 0.67

1.51; − 2.39

 

1480

50–6575

253

31–776

23.3

< 0.88–144

 

399.3

27–2000

S-MRI Spanish MRI score, R-S-ELA Achilles right strain-elastography, L-S-ELA Achilles left strain-elastography, ChT Chitotriosidase

The Pearson test does not show any correlation between the S-ELA grade and other variables, with age (p = .134), with the S-MRI (p = .025), T-score (p = .620), biomarkers: ChT (p = .423), CCL18/PARC (p = .049), Lyso Gb1 (p = .275), Ferritin (p = .151), or time on therapy (p = .174), only with the related physical items and general health in the QoL evaluation (p = .003). Therefore, the S-ELA is an independent variable in GD patients with CFg with a clear impact on the QoL status.

Bone evaluation

The mean S-MRI was 7.1 points (range 0.0–18.0). T-score: mean − 0.67 (range − 2.68–1.51). Advanced bone disease was present in ten patients (37.0%) who showed several vascular complications in the MRI. The osteopenia (T-score − 1 to − 2.5) was registered in eight patients (34.7%).

Analytical data

The genotype distribution was NP_000148:p.Asn409Ser + p.Leu483Pro 59.2%, p.Asn409Ser + other 37.0%, p.Leu483Pro + other 11.1%, other + other 3.7% (see Additional file 1: Table S1).

The mean hemoglobin concentration in males was 14.5 g/dL (range 13.0–17.3) and in females was 13.3 g/dL (range 12.2–14.1). The biochemical inflammatory biomarkers were higher than laboratory cut-off: Ferritin: mean = 399.3 ng/mL (range 27.0–2000.0); ChT: mean = 1480 nmol/mL/h (range 46–6575); CCL18/PARC; mean = 253.1 ng/mL (range 53.0–925.0); Lyso-Gb1: mean = 23.3 ng/mL (range 0.0–144.0) (see Table 1).

Quality of life assessment

A lower score in all dimensions of the QoL in GD patients compared with general population was observed. The QoL results show the lower punctuation in physical role, bodily pain, emotional role, and general health. A significant correlation (p = 0.003) has been observed between the grade of the S-ELA and the general health QoL scale.

Figure 2 shows the graphic analysis of the QoL status of the GD patients compared to the normal population values of reference.
Fig. 2

SF36 questionnaire. Score distribution between GD patients and Spanish general population

Discussion

Chronic fatigue is the most prevalent symptom in patients with Gaucher disease; it appears at any age and usually the patients are not aware of the symptom/sensation, until they perceive the improvement after starting a specific treatment for the disease (either enzymatic replacement therapy or substrate reduction therapy). In some studies, no association was found between enzymatic replacement therapy and the QoL and it is recognized in the surveys made by physicians treating patients with Gaucher disease that fatigue is the most persistent symptom [2].

There are few reports about the significance and origination of this symptom. Many interpretations and theories have been taken into account, regarding the role of different factors such as the altered glyco-lipid metabolism, anemia, bone disease, and comorbidities but there is not a clear explanation yet [1, 2].

Bone affectation is today a well-known and growing area of research on Gaucher disease. There are studies of bone disease pathophysiology, mechanisms of bone infiltration and microenviroment changes, and vascular intraosseous events; decreased bone density has also been extensively examined [1, 4, 5]. Nevertheless, the muscle-tendon function has been little explored in patients with Gaucher disease.

Real-time tissue elastography is a new tool that helps to estimate the internal tissue strain by means of ultrasound radiofrequency. The method is based on the compression of external tissue, with subsequent computation of the strain profile along the transducer axis, which is derived from the cross-correlation analysis of pre- and post-compression. The strain profile can then be converted into an elastic modulus profile by measuring the stress applied by the compressing device and applying certain corrections for the non-uniform stress field. These data can then be translated into color images indicating the degree of elasticity of the tissue.

In short, it is a non-invasive technique that allows the identification of a region of the tissue with a different elasticity than the surrounding areas. This is achieved by simultaneously strain measuring and stress patterns in the tissue portion using an ultrasonic imaging system combined with a pressure-sensing array [9, 10].

The new applications of the elastography provide a low cost non-invasive and not ionization technology as a research tool to assess the mechanical properties of musculotendinous tissues and detect subclinical changes of muscles and tendons. It could potentially be valuable for early diagnosis and for monitoring during rehabilitation medicine [17, 18, 19, 20]).

The Achilles tendon is the most powerful and thick tendon of the musculoskeletal system, but it is the one that most often suffers traumatisms. Up to 50% of athletes can suffer damage in the Achilles tendon to its structure [17, 18]. Also, metabolic chronic diseases such as diabetes can modify the structure and biomechanical properties of the Achilles tendon producing a degenerative tendinopathy. Diabetes produces an architectural disorganization of the tendinous fibers; however, the neuropathy that induces diabetes could justify a decrease in the mobility of the extremities and as a consequence a decrease in tendon stiffness [21, 22].

The structure of the bones, cartilage, and tendons is constituted by collagen fibers, especially in the tendons. As collagen is produced by the fibroblasts and these cells are directly compromised by the lysosomal accumulation of glucosylceramide. It could be thought about a subclinical dysfunction of this tissue secondary to substrate accumulation. Although the purpose of our study was to assess the tendon elasticity, the simultaneous assessment in B mode excluded the existence of glycolipid accumulations that were sonographically detectable.

It is important to consider the role of ionic channels in tissue functioning; it is known that in sphingolipidosis in general, there are defects in the traffic of lipids in the endosome, lysosome, and autophagosomes with accumulation of lipids inside the lysosomes which produces defects in membrane traffic and alteration in homeostasis of Ca2+ [22]. Our hypothesis that tendon dysfunction could be justified in some patients by a glycol-lipid overload in fibroblasts would link with the evidence reflected in the study conducted by our group that shows evidence for such defective KCa3.1 regulation in Fabry disease fibroblasts and in Niemann-Pick C fibroblasts, disturbances in membrane trafficking, or function in the fibroblasts [23]. As well as in another study on KCa3.1 functions performed in type-1 and -3 GD patients, we found a defect in the physiologically occurring upregulation of KCa3.1 during monocyte-to-macrophage differentiation [24, 25], suggesting that KCa3.1 dysregulation is a general feature of sphingolipidosis and cellular pathophysiology.

In the present study, no significant correlation was observed between the tendinous anomaly detected by elastography and the levels of the biomarkers; however, it is noteworthy that over 70% of the studied patients, after many years on therapy, continued showing an increased level of biomarkers. These persistent high levels can be assumed as indirect indicators of substrate accumulation and macrophage hyperactivity; in consequence, these annotations reinforce their theoretical relationship with the symptomatic fatigue.

It is important to remark that in our study there is no age or gender bias; all patients have a long-term exposition to therapy, and they do not have anemia or iron deficiency; however, the persistence of high biomarkers stands out.

The tendon alteration is not related to the intensity of the bone disease or the weakness of the mineral density; also, no relationships with genotype, spleen removal, time on therapy, or comorbidities were found. A possible interpretation of the findings obtained in this study suggests that mechanical overload on lower limbs is the cause of tendon dysfunction.

We propose that exploring tendon elasticity produces useful information in the evaluation of chronic fatigue presented by patients with GD. The detection of subclinical alterations in the Achilles tendon is valuable information to prevent musculoskeletal complications.

The identification of tendon stiffness would be a sign of alarm, focused on the risk of bone complications such as fracture or degenerative arthropathy, and oriented toward the opportunity to propose a program of physical therapeutic exercise as prophylaxis of musculoskeletal complications. Also, strain-elastography could be an interesting and useful tool to monitoring the evolution and response to the physical therapy. It could provide insights for physical medicine and rehabilitation researchers respect to tendon properties and their impact on functionality.

Limitations

As in the majority of GD papers, one of the most severe limitations is the number of patients. The small sample can justify the absence of statistically significant results, which can appear if the number of analyzed patients was higher.

Certain aspects of strain-elastography are controversial, such as its dependence on a well-trained operator, and there can be variability between different operators with impact in the reproducibility of the obtained results. In our study, in order to minimize the variability, all evaluations were carried out with the same device and technique and interpreted by the same expert specialist; this permitted a reliable way to integrate the information collected from the evaluation of bone marrow MRI findings, ultrasonography densitometry, and form the strain-elastography.

This is the first study with strain-elastography performed in Achilles tendon in a group of GD patients.

Conclusions

Strain-elastography is a low-cost sensitive, painless, and fast method to detect tissue alterations. Strain-elastography in Achilles tendon is a conscious method to detect subclinical dysfunction of muscle-tendinous unit that could contribute to explain partially the fatigue symptom in GD.

Intratendinous alteration detected by the strain-elastography is an independent variable in GD patients in this study. The cause of this dysfunction could be probably a mechanical cause related to overload on lower limbs. In consequence, this fact can be a risk factor for the development of skeletal complications.

We propose that exploring tendon elasticity produces useful information in the evaluation of chronic fatigue presented by patients with GD. The detection of subclinical alterations in the Achilles tendon is valuable information to prevent musculoskeletal complications.

A project based on physical activity has been developed in GD patients to increase the functional strength of the lower limbs to achieve greater stability, power, and improvement in physical activities, as well as the reduction of fatigue.

Notes

Authors’ contributions

PG have designed the study interpreted the data and drafting the manuscript. MRE have designed, performed, and interpreted the imaging exams. MAC have collaborated in review and interpretation of data and English editing. J JC and LLF have performed molecular studies and biomarkers; they revised critically the draft. BME have performed and interpreted the quality of life studies. She has revised critically the draft. MPLR have contributed to elastography analysis and design a program of physical therapy activity based in the results. She has revised critically the draft. All authors are in agreement to submission. All authors read and approved the final manuscript.

Funding

The study is been partially supported by a grant from FEETEG.

Ethics approval and consent to participate

Local ethics committee (CEICA).

Consent for publication

Informed consent was obtained from all the participants.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

13018_2019_1452_MOESM1_ESM.docx (34 kb)
Additional file 1: Table S1. General characteristics.

References

  1. 1.
    Pastores GM, Hughes DA. Gaucher disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington,Seattle; 2000. [updated 2018 Jun 21]; 1993–2019. Available from http://www.ncbi.nlm.nih.gov/books/NBK1269/.Google Scholar
  2. 2.
    Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:39.CrossRefGoogle Scholar
  3. 3.
    Zion YC, Pappadopulos E, Wajnrajch M, Rosenbaum H. Rethinking fatigue in Gaucher disease. Orphanet J Rare Dis. 2016;11:53.CrossRefGoogle Scholar
  4. 4.
    Andrade-Campos M, Valero E, Roca M, Giraldo P, Spanish group on Gaucher Disease. The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises. Blood Cells Mol Dis. 2018;68:126–34.CrossRefGoogle Scholar
  5. 5.
    Baldini M, Casirati G, Ulivieri FM, et al. Skeletal involvement in type 1 Gaucher disease: not just bone mineral density. Blood Cells Mol Dis. 2018;68:148–52.CrossRefGoogle Scholar
  6. 6.
    Giraldo P, Solano V, Pérez-Calvo JI, et al. Spanish group on Gaucher disease. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005;14:453–62.CrossRefGoogle Scholar
  7. 7.
    Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ 2nd. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998;7:521–34.CrossRefGoogle Scholar
  8. 8.
    Giraldo P. Grupo de Trabajo de las Guías de Actuación [Guidelines for type 1 Gaucher's disease]. Med Clin (Barc). 2011;137 Suppl 1:55–60.CrossRefGoogle Scholar
  9. 9.
    Drakonaki E. Ultrasound elastography for imaging tendons and muscles. J Ultrasonographyy. 2012;12:214–25.CrossRefGoogle Scholar
  10. 10.
    Petrescu PH, Izvernariu DA, Iancu C, et al. Evaluation of normal and pathological Achilles tendon by real-time shear wave elastography. Rom J Morphol Embryol. 2016;57(2 Suppl):785–90.PubMedGoogle Scholar
  11. 11.
    Roca M, Mota J, Alfonso P, et al. S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol. 2007;62:132–7.CrossRefGoogle Scholar
  12. 12.
    Hans D, Baim S. Quantitative ultrasound (QUS) in the management of osteoporosis and assessment of fracture risk. J Clin Densitom. 2017;20:322–33.CrossRefGoogle Scholar
  13. 13.
    Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994;93:1288–92.CrossRefGoogle Scholar
  14. 14.
    Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33–9.CrossRefGoogle Scholar
  15. 15.
    Dekker N, van Dussen L, Hollak CE, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118–27.CrossRefGoogle Scholar
  16. 16.
    Alonso J, Prieto L, Antó JM. La version española del SF-36 Health Survey (Cuestionario de Salud SF36). Un instrumento para la medida de los resultados clínicos. Med Clin (Barc). 1995;104:771–6.Google Scholar
  17. 17.
    Archambault JM, Wiley JP, Bray RC, et al. Can sonography predict the outcome in patients with achillodynia? J Clin Ultrasound. 1998;26:335–9.CrossRefGoogle Scholar
  18. 18.
    Domenichini R, Pialat JB, Podda A, Aubry S. Ultrasound elastography in tendon pathology: state of the art. Skeletal Radiol. 2017;46:1643–55.CrossRefGoogle Scholar
  19. 19.
    Prado-Costa R, Rebelo J, Monteiro-Barroso J, Preto AS. Ultrasound elastography: compression elastography and shear-wave elastography in the assessment of tendon injury. Insights into Imaging. 2018;9:791–814.CrossRefGoogle Scholar
  20. 20.
    Winn N, Lalam R, Cassar-Pullicino V. Sonoelastography in the musculoskeletal system: current role and future directions. World J Radiol. 2016;8:868–79.CrossRefGoogle Scholar
  21. 21.
    Ooi CC, Schneider ME, Malliaras P, et al. Prevalence of morphological and mechanical stiffness alterations of mid Achilles tendons in asymptomatic marathon runners before and after a competition. Skelet Radiol. 2015;44:1119–27.CrossRefGoogle Scholar
  22. 22.
    Balaban M, Idilman IS, Ipek A, et al. Elastographic findings of Achilles tendons in asymptomatic professional male volleyball players. J Ultrasound Med. 2016;35:2623–8.CrossRefGoogle Scholar
  23. 23.
    Shen D, Wang X, Li X, Zhang X, Yao Z, Dibble S, et al. Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat Commun. 2012;3:731.CrossRefGoogle Scholar
  24. 24.
    Oliván-Viguera A, Lozano-Gerona J, López de Frutos L, Cebolla JJ, Irún P, Abarca-Lachen E, et al. Inhibition of intermediate-conductance calcium-activated K channel (KCa3.1) and fibroblast mitogenesis by α-linolenic acid and alterations of channel expression in the lysosomal storage disorders, Fabry disease, and Niemann Pick C. Front Physiol. 2017;8:39.CrossRefGoogle Scholar
  25. 25.
    Oliván-Viguera A, Alfonso P, Giraldo P, Köhler R. Reduced KCa3.1 channels functions in monocytes/macrophages in Gaucher disease. Mol. Genet. Metab. 2015;114:S87.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Mercedes Roca-Espiau
    • 1
    • 2
  • Marcio Andrade-Campos
    • 1
    • 3
    • 4
  • Jorge J. Cebolla
    • 1
    • 3
    • 5
  • Laura López de Frutos
    • 1
    • 3
  • Blanca Medrano-Engay
    • 1
    • 3
  • Maria-Pilar López-Royo
    • 3
    • 6
  • Pilar Giraldo
    • 1
    • 3
    Email author
  1. 1.Fundación Española Estudio y Tratamiento de la Enfermedad de Gaucher y Otras Lisosomales (FEETEG)ZaragozaSpain
  2. 2.Radiologic Centre CEMEDIZaragozaSpain
  3. 3.Grupo de Investigación en Enfermedad de Gaucher (GIIS-012)Unidad de Investigación Traslacional, Fundación Instituto de Investigación Sanitaria AragónZaragozaSpain
  4. 4.Departamento de HematologíaHospital del MarBarcelonaSpain
  5. 5.Departamento de Bioquímica, Biología Molecular y Celular, Facultad de CienciasUniversidad de ZaragozaZaragozaSpain
  6. 6.iPhysio GroupUniversidad San JorgeZaragozaSpain

Personalised recommendations